Gilead's NDA for ambrisentan damages Encysive shares

With its NDA for Thelin hung up at the FDA, Encysive saw its stock price slip after Gilead announced that the agency had accepted its application for a competing pulmonary arterial hypertension drug, ambrisentan. The FDA is giving ambrisentan a priority review. Analysts criticized Encysive for losing its lead over ambrisentan. Thelin has been approved in Europe but its FDA application has been delayed a by year.

- here's the AP report on the competition

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.